Efficacy and safety of linezolid in immunocompromised children with cancer

Pediatrics International

Volumn 52, Issue 5, 2010, Pages 694-698

  Moschovi, Maria ^a   Trimis, Georgios ^a   Tsotra, Maria ^a   Chatzi, Fotini ^a   Karamolegou, Kalliopi ^a   Santou, Antina ^a   Tourkantoni, Natalia ^a   Chrousos, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

cancer; children; linezolid

Indexed keywords

LINEZOLID; MEROPENEM; METICILLIN; VANCOMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; BLEEDING; BRAIN TUMOR; BURKITT LYMPHOMA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS; FEMALE; GRAM POSITIVE INFECTION; HISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; INFANT; MALE; NAUSEA; OVARY TUMOR; PRIORITY JOURNAL; RASH; RHABDOMYOSARCOMA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; VOMITING;

ACETAMIDES; AGE FACTORS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFUSIONS, INTRAVENOUS; MALE; OXAZOLIDINONES; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957366584     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03097.x     Document Type: Article

References (32)

1. Santolaya ME, Alvarez AM, Avilés CL et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin. Infect. Dis. 2002 35 : 678 683.
2. Santolaya ME, Alvarez AM, Becker A et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J. Clin. Oncol. 2001 19 : 3415 3421.
3. Moellering RC Jr., Graybill JR, McGowan JE Jr., Corey L, American Society for Microbiology. Antimicrobial resistance prevention initiative - An update: Proceedings of an expert panel on resistance. Am. J. Infect. Control. 2007 35 : S1 23.
4. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int. J. Antimicrob. Agents. 2007 29 : 501 509.
5. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann. Oncol. 2003 14 : 795 801.
6. Bhavnani SM, Ballow CH. New agents for Gram-positive bacteria. Curr. Opin. Microbiol. 2000 3 : 528 534.
7. Moellering RC. Linezolid: The first oxazolidinone antimicrobial. Ann. Intern. Med. 2003 138 : 135 142.
8. Clemett D, Markham A. Linezolid. Drugs 2000 59 : 815 828.
9. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J. Antimicrob. Chemother. 2001 47 : 77 81.
10. Cuny C, Witte W. In vitro activity of linezolid against staphylococci. Clin. Microbiol. Infect. 2000 6 : 331 333.
11. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents. Chemother. 1996 40 : 1745 1747.
12. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J. Antimicrob. Chemother. 2000 46 : 931 940.
13. Velissariou IM. Linezolid in children: Recent patents and advances. Recent. Pat. Antiinfect. Drug. Discov. 2007 1 : 73 7.
14. Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl. S193 200.
15. Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert. Opin. Pharmacother. 2009 10 : 785 796.
16. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther. Clin. Risk. Manag. 2006 2 : 455 464.
17. Kaplan SL, Deville JG, Yogev R et al. Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J. 2003 22 : 677 686.
18. Kaplan SL, Patterson L, Edwards KM et al. Linezolid Pediatric Pneumonia Study Group. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr. Infect. Dis. J. 2001 20 : 488 494.
19. Chen CJ, Chiu CH, Lin TY, Lee ZL, Yang WE, Huang YC. Experience with linezolid therapy in children with osteoarticular infections. Pediatr. Infect. Dis. J. 2007 26 : 985 988.
20. Kaplan SL, Afghani B, Lopez P et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl. S178 85.
21. Jantausch BA, Deville J, Adler S et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl. S164 71.
22. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann. Pharmacother. 2004 38 : 989 991.
23. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: An overview. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl. S153 7.
24. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J. 2006 25 : 562 564.
25. Lawyer MC, Lawyer EZ. Linezolid and reversible myelosuppression. J. Am. Med. Assoc. 2001 286 : 1974.
26. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob. Agents. Chemother. 2002 46 : 2723 2726.
27. Tavil B, Balci YI, Yildirim I et al. Linezolid-induced reversible bicytopenia in a 4-year-old boy with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr. Hematol. Oncol. 2008 25 : 67 71.
28. Meissner HC, Townsend T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl. S186 92.
29. Linam WM, Wesselkamper K, Gerber MA. Peripheral Neuropathy in an Adolescent Treated With Linezolid. Pediatr. Infect. Dis. J. 2009 28 : 149 151.
30. Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. Antimicrob. Chemother. 2004 53 : 1114 1115.
31. Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr. Infect. Dis. J. 2009 28 : 149 151.
32. Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 2005 353 : 2305 2306.